Treatment strategies for Parkinson’s disease often aim to restore dopaminergic activity, primarily using the dopamine precursor levodopa, dopamine agonists, or monoamine oxidase B (MAO-B) inhibitors, which all help manage motor symptoms by compensating for the impaired synaptic release caused by α-synuclein aggregation (Fig. 4) [269–271]. The gene discussed is MAOB; the disease is Parkinson disease.